Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMAGLPW)

Drug Name
RO-316233 Drug Info
Synonyms
119139-23-0; bisindolylmaleimide iv; 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-dione; Arcyriarubin A; 3,4-Bis(3-indolyl)maleimide; 3,4-Di-1H-indol-3-yl-1H-pyrrole-2,5-dione; UNII-MBK3OO5K8T; BIM IV; 3,4-bis(1H-indol-3-yl)pyrrole-2,5-dione; MBK3OO5K8T; CHEMBL266487; 3,4-bis(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; DQYBRTASHMYDJG-UHFFFAOYSA-N; 2,3-bis(1H-Indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-; Ro-31-6233; AK-15401; 3,4-bis(3-indolyl)-1H-pyrrole-2,5-dione; Bisindoylmaleimide; Bisindolyl deriv. 3
Cross-matching ID
PubChem CID
2399
ChEBI ID
CHEMBL266487
CAS Number
CAS 119139-23-0
TTD Drug ID
D0L8HO

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Ribosome 2.54 0.00e+0 113/158 (71.52%) RPS5;MRPL12;MRPS16;...
Oxidative phosphorylation 2.25 0.00e+0 93/133 (69.92%) ATP6V0B;NDUFA3;NDUFB1;...
RNA polymerase 2.17 0.00e+0 23/31 (74.19%) POLR2L;POLR2G;POLR2H;...
Parkinson disease 1.84 9.40e-3 176/249 (70.68%) TUBB2A;PSMB3;NDUFA3;...
Huntington disease 1.82 8.60e-3 233/306 (76.14%) GPX7;POLR2L;POLR2G;...
Ribosome biogenesis in eukaryotes 1.81 8.95e-3 52/108 (48.15%) NOP10;NXT1;POP4;...
Metabolism of xenobiotics by cytochrome P450 1.74 2.38e-2 49/77 (63.64%) CYP1B1;GSTT2;UGT2B28;...
Ubiquinone and other terpenoid-quinone biosynthesis 1.73 2.22e-2 9/11 (81.82%) NQO1;VKORC1;GGCX;...
Steroid biosynthesis 1.71 2.45e-2 19/20 (95%) SC5D;MSMO1;EBP;...
Axon guidance -1.65 4.50e-2 151/182 (82.97%) DCC;ROCK1;PLXNC1;...
Natural killer cell mediated cytotoxicity -1.65 4.42e-2 99/131 (75.57%) PPP3R1;LCP2;SOS2;...
AGE-RAGE signaling pathway in diabetic complications -1.65 4.57e-2 97/100 (97%) PRKCZ;COL3A1;PRKCB;...
Thyroid hormone signaling pathway -1.66 4.53e-2 112/121 (92.56%) MAPK1;CASP9;ATP1A3;...
Cell adhesion molecules -1.66 4.64e-2 118/148 (79.73%) HLA-C;CNTN1;CNTNAP1;...
Adrenergic signaling in cardiomyocytes -1.67 4.66e-2 130/150 (86.67%) MYH7;ADCY7;MAPK11;...
Allograft rejection -1.67 4.57e-2 32/38 (84.21%) IL5;HLA-F;CD86;...
Epstein-Barr virus infection -1.68 4.60e-2 189/202 (93.56%) NCOR2;MAPK14;BLNK;...
Graft-versus-host disease -1.70 4.26e-2 32/42 (76.19%) HLA-F;CD86;HLA-DPA1;...
Type I diabetes mellitus -1.71 3.86e-2 38/43 (88.37%) CD86;HLA-DPA1;HLA-A;...
Wnt signaling pathway -1.71 3.98e-2 124/166 (74.7%) PRKACA;BTRC;INVS;...
Yersinia infection -1.72 4.19e-2 120/137 (87.59%) MAPK1;IKBKB;NLRP3;...
Phosphatidylinositol signaling system -1.72 4.35e-2 82/97 (84.54%) INPP5D;CALML4;PIK3R2;...
Growth hormone synthesis, secretion and action -1.73 4.52e-2 108/119 (90.76%) ADCY7;MAPK11;SOCS3;...
Primary immunodeficiency -1.75 3.84e-2 33/38 (86.84%) AICDA;CD8A;BLNK;...
Carbohydrate digestion and absorption -1.75 4.10e-2 37/47 (78.72%) PRKCB;PIK3CB;PIK3R3;...
Insulin secretion -1.75 4.29e-2 75/86 (87.21%) SLC2A2;PRKACA;ATP1A1;...
Endocrine and other factor-regulated calcium reabsorpti... -1.78 3.87e-2 49/53 (92.45%) AP2A2;PRKACA;ATP1A1;...
Gastric acid secretion -1.78 4.08e-2 63/76 (82.89%) ADCY7;ACTB;CALML4;...
Human papillomavirus infection -1.79 3.94e-2 284/331 (85.8%) PTGER4;BCAP31;LAMC1;...
Inositol phosphate metabolism -1.81 3.08e-2 66/73 (90.41%) PIK3C2A;PTEN;MTMR3;...
Th1 and Th2 cell differentiation -1.84 2.49e-2 80/92 (86.96%) MAPK1;IKBKB;IL5;...
Arrhythmogenic right ventricular cardiomyopathy -1.86 2.27e-2 70/77 (90.91%) DSG2;ITGA2;ITGA9;...
Platelet activation -1.87 2.20e-2 106/124 (85.48%) PPP1CC;PTGS1;GP5;...
Focal adhesion -1.87 2.56e-2 180/201 (89.55%) MAPK1;KDR;PTEN;...
Leishmaniasis -1.88 3.08e-2 67/77 (87.01%) MAPK14;FOS;ITGB1;...
Proteoglycans in cancer -1.90 3.49e-2 172/205 (83.9%) CBL;RHOA;MAPK11;...
Histidine metabolism -1.92 3.73e-2 16/22 (72.73%) ALDH2;ALDH9A1;HAL;...
Salivary secretion -1.94 4.19e-2 76/93 (81.72%) PRKG1;PRKACA;CST2;...
ECM-receptor interaction -2.00 4.19e-2 80/88 (90.91%) CD44;LAMC1;HMMR;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HAP1 CVCL_Y019 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 CDK4 (-) 1 CVCL_SI36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 HDAC5 (-) 1 CVCL_SR11 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 ITGA4 (-) 1 CVCL_ST27 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 MAPK8 (-) 1 CVCL_SW99 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PIK3CA (-) 1 CVCL_TD60 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKACA (-) 1 CVCL_TG70 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKCQ (-) CVCL_TG92 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 RELA (-) 1 CVCL_TI75 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 SRC (-) 1 CVCL_TQ36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 TP53 (-) 1 CVCL_RJ70 Homo sapiens 0.66uM - 3.33uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.66uM - 10uM 6H, 24H